Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz

Patent Law

: IPBiz

Barr to challenge Anesta over AMRIX (cyclobenzaprine)

By Lawrence B. Ebert, Esq.

MarketWatch: Barr Pharmaceuticals, Inc. (of Montvale, NJ) on Nov. 26 confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix(R) (cyclobenzaprine hydrochloride) extended-release capsules, 15mg and 30mg.

This is through a lawsuit. MarketWatch noted: On November 26, 2008, Eurand, Inc., Cephalon, Inc., and Anesta AG filed suit in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Full post as published by IPBiz on November 26, 2008 (boomark / email).